These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 11264150)
1. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Deguchi H; Fernández JA; Pabinger I; Heit JA; Griffin JH Blood; 2001 Apr; 97(7):1907-14. PubMed ID: 11264150 [TBL] [Abstract][Full Text] [Related]
2. Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. Deguchi H; Bouma BN; Middeldorp S; Lee YM; Griffin JH J Thromb Haemost; 2005 May; 3(5):935-8. PubMed ID: 15869587 [TBL] [Abstract][Full Text] [Related]
3. Plasma glycolipids levels: new factors regulating the protein C anticoagulant pathway and determining thrombotic risk. Esmon CT Blood; 2001 Apr; 97(7):1905. PubMed ID: 11264146 [No Abstract] [Full Text] [Related]
4. Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. Deguchi H; Fernández JA; Griffin JH J Biol Chem; 2002 Mar; 277(11):8861-5. PubMed ID: 11741960 [TBL] [Abstract][Full Text] [Related]
5. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463 [TBL] [Abstract][Full Text] [Related]
6. Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles. Yegneswaran S; Deguchi H; Griffin JH J Biol Chem; 2003 Apr; 278(17):14614-21. PubMed ID: 12560338 [TBL] [Abstract][Full Text] [Related]
7. Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Tufano A; Guida A; Coppola A; Nardo A; Di Capua M; Quintavalle G; Di Minno MN; Cerbone AM; Di Minno G Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s337-42. PubMed ID: 23399370 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Galli M; Ruggeri L; Barbui T Blood; 1998 Mar; 91(6):1999-2004. PubMed ID: 9490682 [TBL] [Abstract][Full Text] [Related]
9. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. Raps M; Helmerhorst F; Fleischer K; Thomassen S; Rosendaal F; Rosing J; Ballieux B; VAN Vliet H J Thromb Haemost; 2012 Jun; 10(6):992-7. PubMed ID: 22469296 [TBL] [Abstract][Full Text] [Related]
10. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Margaglione M; Brancaccio V; De Lucia D; Martinelli I; Ciampa A; Grandone E; Di Minno G Chest; 2000 Nov; 118(5):1405-11. PubMed ID: 11083693 [TBL] [Abstract][Full Text] [Related]
16. Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives. Stegeman BH; Helmerhorst FM; Vos HL; Rosendaal FR; Van Hylckama Vlieg A J Thromb Haemost; 2012 Oct; 10(10):2061-7. PubMed ID: 22882730 [TBL] [Abstract][Full Text] [Related]
17. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335 [TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Tans G; van Hylckama Vlieg A; Thomassen MC; Curvers J; Bertina RM; Rosing J; Rosendaal FR Br J Haematol; 2003 Aug; 122(3):465-70. PubMed ID: 12877675 [TBL] [Abstract][Full Text] [Related]